查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862584

新型藥物遞送系統（NDDS）市場在癌症治療的應用—按產品類型、藥物類型、應用和技術平台分類—2025年至2032年全球預測

NDDS in Cancer Therapy Market by Product Type, Drug Type, Application, Technology Platform - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，用於癌症治療的 NDDS 市場將成長至 329 億美元，複合年成長率為 13.72%。

關鍵市場統計數據
基準年 2024 117.5億美元
預計年份：2025年 133.5億美元
預測年份 2032 329億美元
複合年成長率 (%) 13.72%

本文全面概述了奈米載體和基於裝置的系統中的多學科平台創新如何重新定義腫瘤治療策略和臨床應用。

新一代藥物遞送系統（NDDS）透過實現更精準、高效且以患者為中心的干涉措施，正在重塑腫瘤治療策略。載體結構和製劑科學的進步實現了對藥物動力學的可控控制、增強了腫瘤蓄積並降低了脫靶毒性，從而拓寬了現有細胞毒性藥物和新型生物製藥的治療指數。這些優勢的實現得益於多種材料平台，包括基於樹狀聚合物的支架、仿生外泌體材料、脂質奈米載體和傳統脂質體，以及金屬奈米顆粒結構、膠束、奈米乳液和聚合物奈米顆粒系統。每種平台都具有獨特的理化性質，這些性質會影響藥物的載藥量、穩定性、循環時間和組織滲透性。

同樣重要的是，現代奈米藥物遞送系統（NDDS）能夠遞送的藥物種類繁多。基因治療藥物、單株抗體、寡核苷酸藥物、siRNA構建體和小分子化療現在已被常規地整合到工程化載體中，實現聯合治療和多種作用機制。這些有效載荷支持化療、免疫療法、動態療法、放射線治療和標靶治療等臨床應用，通常需要客製化的遞送設計才能到達細胞內和腫瘤微環境標靶。除了材料和有效載荷方面的創新之外，新興技術平台也層出不窮，例如可植入的藥物儲存系統、可注射懸浮液、微針系統和基於奈米技術的構建體。在奈米技術領域，設計選擇側重於主動靶向策略（利用配體定向或受體介導的機制靶向特定細胞群）或被動靶向策略（利用尺寸、表面化學性質以及增強的滲透性和滯留性將藥物濃縮在腫瘤組織中）。

本導言概述了工程學、生物學、監管科學和臨床實踐交匯融合的現狀。轉化醫學的進展不僅取決於在對照研究中證明療效和安全性的提升，還取決於解決下游挑戰，例如可擴展的生產、可重複的表徵以及監管合規性。因此，從藥物發現研究人員和製劑工程師到臨床營運和商業團隊，相關人員必須在日益多學科的協作路徑中攜手合作，才能推動新型藥物遞送系統（NDDS）從概念走向臨床。

這是一個重大的技術、臨床和製造轉折點，它將重塑癌症治療中標靶遞送和聯合治療的開發和商業化進程。

腫瘤藥物遞送領域正經歷著一場變革性的轉變，其驅動力來自於技術融合、監管演變和臨床範式的轉變。主動標標靶化策略的成熟是這項轉變的關鍵轉捩點。配體介導和受體導向的策略正超越概念驗證，並在特定適應症中展現出可重複的標靶結合和更佳的治療窗口。同時，被動標靶化策略也在不斷發展，透過改進顆粒設計和表面化學，延長了藥物的循環半衰期，並實現了可調控的腫瘤滲透動力學。這些科學進步得益於有效載荷模式的同步發展，特別是核酸療法（如siRNA和寡核苷酸藥物）與脂質和聚合物載體的整合，從而實現了傳統製劑無法實現的細胞內基因調控。

另一個重大轉變是基於新型藥物遞送系統（NDDS）的聯合治療的重要性日益凸顯，這種療法能夠同時遞送免疫調節劑和細胞毒性或標靶藥物，從而重塑腫瘤微環境。在此背景下，製劑創新與免疫治療機制的協同作用正在催生新的臨床試驗設計和監管考慮。同時，植入式儲庫系統和微針平台的進步正在拓展局部給藥的途徑，預計將降低全身暴露並提高病患的用藥依從性。從生產和商業化的角度來看，模組化和連續生產技術的投資正在增加，以提高批次間一致性並擴大生產規模，同時嚴格控制關鍵品質屬性。最後，數據驅動的個人化治療，包括基於生物標記的患者選擇和伴隨診斷，正成為臨床開發策略的基礎，確保藥物遞送創新能夠精準地應用於最有可能獲益的患者群體。這些變革共同作用，使藥物遞送從一種外圍製劑技術轉變為下一代腫瘤治療的核心驅動力。

分析2025年關稅政策變化對先進腫瘤遞送系統供應鏈韌性、籌資策略和商業性考量的影響

美國2025年實施的新關稅為新型注射給藥系統（NDDS）生態系統帶來了一系列營運和策略壓力，影響了供應鏈、籌資策略和成本結構。即時的營運影響體現在對一些通常透過全球供應商採購的特種原料和先進輔料的採購上，例如某些脂質、特種聚合物以及前置作業時間，採購團隊優先考慮供應商多元化、選擇替代供應商以及達成涉及共同投資本地生產能力的雙邊協議。這些調整加速了關於地域多角化的討論，並促使人們更加關注在國內或附近建立強大的關鍵組件生產能力和契約製造活動。

在研發和臨床專案中，關稅主導的環境凸顯了靈活配方方法的重要性，這些方法可以減少對單一供應來源的依賴。研發團隊加快了對替代化學成分和生產流程的評估，以降低關稅波動帶來的風險。同時，企業更積極尋求策略聯盟和授權協議，以確保獲得關鍵技術並分擔本地生產投資的財務負擔。從商業性角度來看，定價策略和合約談判必須考慮潛在的利潤率壓縮，同時也要在全球市場保持競爭力。這些趨勢也影響了區域擴張決策，在擁有優惠貿易協定和成熟生產生態系統的地區，產能擴張計畫越來越受歡迎。最終，關稅環境迫使企業在短期成本管理與長期投資之間取得平衡，這些投資包括增強供應鏈的穩健性、確保新製造地符合監管要求以及進行選擇性垂直整合以保護關鍵能力。

基於細分市場的深刻觀點揭示了產品類別、有效載荷類別、臨床應用和平台技術如何協同作用，從而指導策略發展重點。

清晰的細分對於理解新型經皮給藥系統（NDDS）領域中技術價值與臨床應用前景的交會點至關重要。依產品類型分析，可以發現不同的價值提案：樹狀聚合物和聚合物奈米顆粒可提供可調控的結構，實現精準的藥物負載和可控釋放；受外泌體啟發的平台可提供仿生界面，用於免疫調節和細胞內轉運；脂質奈米載體和脂質身體因其良好的生物相容性和監管記錄，在核酸和小分子有效載荷的遞送中發揮著核心作用；金屬奈米顆粒可透過造影劑和光熱治療實現診斷和治療功能；膠束和奈米乳液為溶解疏水性化療藥物提供了低成本、可擴展的選擇。每個類別都有其獨特的開發路徑和實用化障礙，因此，開發重點必須使平台特性與尚未滿足的臨床需求相符。

按藥物類型分類，先進的包封技術和核內體逃脫解決方案對於將基因療法和siRNA整合到遞送載體中至關重要。同時，單株抗體和寡核苷酸藥物對穩定性和結合能力有著獨特的要求。相較之下，小分子化療通常受益於能夠調節藥物動力學的載體，從而降低全身毒性並增強腫瘤暴露。按應用領域分類，可以發現一些機會叢集：化療仍然是提高安全性和靶向性的主要應用領域；免疫療法受益於能夠調節抗原呈現和免疫細胞轉運的遞送系統；動態療法和放射線治療輔助劑受益於能夠將光敏劑和放射敏劑定位在腫瘤微環境中的載體；標靶治療擴大與奈米載體結合使用，從而實現對傳統的遞點載體。

對技術平台的評估揭示了實施路徑和臨床應用的促進因素。植入式藥物儲存系統可提供持續的局部濃度，有助於固態腫瘤的部位特異性控制。注射式混懸液和微針系統可支持門診治療，提高病患依從性，減少對輸液中心的依賴。在更廣泛的奈米技術領域，被動靶向和主動標靶化之間的設計權衡決定了療效結果。被動標靶化利用膠體標靶化和尺寸來發揮腫瘤生理特性，而主動標標靶化則利用配體定向或受體介導的機制來增強細胞特異性。因此，基於產品類型、藥物類別、適應症和平台技術的分層細分，可以指導基於技術可行性、監管先例和患者照護模式的投資優先排序和臨床應用策略。

區域趨勢和策略要務將影響全球三大市場區域臨床開發、生產規模化和商業化部署的調整方式。

區域趨勢顯著影響新型藥物遞送系統（NDDS）的研發路徑、合作夥伴選擇和商業化策略。在美洲，強大的創業投資系統、密集的生物技術叢集和活躍的臨床試驗環境為快速轉化應用提供了支持。法規結構強調對新型療法的早期介入和指導，而專業的合約研發生產機構（CDMO）擁有充足的產能來支持規模化生產。這些因素共同創造了一個First-in-Class技術快速達成臨床里程碑並吸引策略夥伴關係的環境。

歐洲、中東和非洲地區呈現出多元化的格局，強大的監管專長和學術研究中心推動科學創新，但市場進入和報銷框架在不同司法管轄區之間存在顯著差異。歐洲的創新者通常受益於促進轉化科學發展的合作網路和公私合營，而該地區的新興市場則可能優先考慮成本效益高且擴充性的交付方式，以解決准入和基礎設施方面的限制。

亞太地區的特點是生產能力快速擴張、政府主導的生物技術基礎設施大量投資，以及龐大的患者群體，這些都為臨床開發和真實世界證據的生成提供了極具吸引力的優勢。多個市場的主要企業在製劑開發和高通量生產方面展現出強大的實力，從而支持了全球供應多元化策略。在全部區域，不同的商業化路徑——從已開發市場高階、慷慨的上市模式到某些新興市場務實、成本驅動的策略——需要採取適應性策略，使監管方法、夥伴關係模式和生產佈局與當地的准入和報銷環境相契合。

主要企業如何透過策略行動、夥伴關係模式和營運重點，將其交付平台的優勢轉化為臨床和商業性優勢。

腸外給藥系統（NDDS）生態系的競爭呈現出垂直整合、專業化分工和策略聯盟並存的格局。現有製藥公司積極尋求引進許可和選擇性收購，以整合與其治療產品線互補的給藥技術；而專業合約開發公司和技術驅動型Start-Ups則專注於平台成熟和技術驗證。一個明顯的趨勢是，聯盟將製劑技術與臨床開發能力結合，從而加快概念驗證並降低首次人體臨床試驗的風險。

主要企業面臨的關鍵營運挑戰包括：投資於穩健的CMC（化學、製造和控制）開發、嚴格表徵關鍵品質屬性，以及儘早與監管機構協調制定複雜製劑的可比性策略。進行臨床階段新型藥物遞送系統（NDDS）計畫的企業通常會投資於正交分析和製程控制方法，以降低變異性並促進規模化生產。智慧財產權策略通常需要在核心化合物保護與針對性的方法和用途專利之間取得平衡，並以自由實施評估來指導合作和授權談判。此外，與診斷和生物標記提供者的跨行業合作正在指南伴隨診斷策略，將遞送創新與患者選擇標準聯繫起來。總而言之，這些趨勢凸顯了在技術、監管和商業規劃方面採取綜合方法的重要性，以便將平台優勢轉化為永續的市場應用。

為經營團隊提供切實可行、影響深遠的策略建議，以加速先進腫瘤治療領域的研發進程，降低營運風險，並確保在監管和商業性獲得優勢。

腸外給藥系統 (NDDS) 領域的領導企業必須採取切實可行的策略，使技術創新與商業性可行性和監管現實相契合。首先，他們應優先考慮早期和持續的監管溝通，以明確可接受的終點指標、對照策略和分析預期。這將減少後期階段的意外情況，並加快研發進程。其次，他們應投資於模組化、可擴展的生產解決方案和多源採購策略，以降低供應中斷和關稅波動帶來的風險。第三，他們應設計整合基於生物標記的患者選擇和適應性研究設計的臨床開發項目，以提高訊號檢測能力並最佳化資源分配。第四，他們應尋求能夠結合製劑技術和臨床開發能力的夥伴關係，特別是與在植入式和微針平台設備整合方面擁有經驗的團隊合作。

第五，使產品組合提案與差異化價值主張保持一致，並將資源集中在有望在治療指數和患者體驗方面帶來臨床意義顯著改善的平台-有效載荷組合。第六，加強智慧財產權和資料獨佔策略，以涵蓋製劑和生產方面的創新，並考慮在平台模組化可能導致競爭的情況下提交防禦性申請。第七，將真實世界數據和衛生經濟學規劃納入研發流程，以支持與支付方的討論和報銷模式的發展。最後，組成跨學科團隊，連結材料科學、轉化生物學、監管事務和商業策略，以確保技術進步能夠轉化為切實可行的治療方案和永續的經營模式。

採用穩健的多學科研究途徑，結合專家訪談、技術成熟度評估和證據綜合，以檢驗轉化和商業性結論。

本執行摘要的研究整合了多方面的證據，從而得出嚴謹且切實可行的見解。主要資訊來源包括對來自生物技術、製藥和合約服務機構的製劑科學家、臨床開發總監、生產主管和監管專家的結構化訪談。研究探討了技術挑戰、商業化重點以及預期的開發策略變化。次要研究則利用同儕審查文獻、臨床試驗註冊資訊、專利申請和已發布的監管指導文件，對平台性能、臨床終點和核准途徑的趨勢進行三角驗證。

此分析方法結合了定性綜合和技術成熟度評估，以評估實用化障礙，包括封裝效率、穩定性以及可生產性。透過情境分析，檢驗了供應鏈和政策影響，情境分析考慮了原料採購、區域生產能力和貿易政策的變化。主要發現透過與相關領域專家研討會以及檢驗近期成功將新型藥物實用化系統（NDDS）商業化為臨床和商業產品的案例研究得到驗證。這種多方面的方法確保了結論是基於技術現實，並得到相關人員的支持，且適用於研發和商業化過程中的策略決策。

整合技術進步、臨床策略和營運準備之間的相互作用機制，以確定哪些未來的醫療服務創新將實際改變癌症治療。

腫瘤學領域新一代藥物遞送系統的發展趨勢預示著一個新時代的到來，在這個時代，遞送技術的創新對於治療效果、患者體驗和商業性差異化至關重要。樹狀聚合物、脂質載體、外泌體衍生結構和植入式裝置的技術進步，使得藥物暴露在精確的時空控制成為可能；而核酸療法和靶向生技藥品的引入，則拓展了可靶向的分子通路範圍。與這些技術進步相伴而生的是臨床開發模式的轉變，這種轉變強調以生物標記為指導的患者選擇，以及整合免疫調節和局部遞送的聯合治療策略。

然而，要充分發揮新型藥物遞送系統（NDDS）的潛力，需要在研發初期階段就高度重視生產規模化、可靠的表徵方法以及與監管機構的溝通。政策變化和貿易趨勢凸顯了建立具有韌性的供應鏈和靈活籌資策略的必要性。那些將嚴謹的CMC（化學、生產和品管）實踐與策略夥伴關係、適應性臨床設計以及以患者為中心的給藥模式相結合的機構，將更有能力將平台優勢轉化為切實的臨床和商業性成果。儘管該領域充滿創新潛力，但成功與否最終取決於能否將卓越的技術與監管、生產和市場進入等方面的實際執行力有效結合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 腫瘤微環境響應型奈米顆粒平台在增強選擇性藥物釋放的臨床應用
  • 開發一種多功能脂質奈米顆粒系統，可同時將siRNA和化療藥物遞送至抗藥性腫瘤
  • 受外泌體啟發而設計的仿生奈米載體用於靶向免疫調節藥物遞送
  • 將即時成像技術整合到用於治療監測的治療性診斷奈米顆粒藥物傳遞系統中
  • 利用腫瘤pH值和酵素觸發機制，透過開發刺激響應型高分子奈米微胞實現按需藥物釋放
  • 利用結合新抗原胜肽和佐劑的個人化奈米顆粒疫苗進行癌症免疫治療

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的癌症治療領域新型藥物遞送系統市場

  • 樹狀聚合物
  • 外泌體
  • 脂質奈米載體
  • 脂質體
  • 金屬奈米粒子
  • 米歇爾
  • 奈米乳液
  • 聚合物奈米粒子

9. 依藥物類型分類的癌症治療領域新型藥物遞送系統市場

  • 基因治療藥物
  • 單株抗體
  • 寡核苷酸藥物
  • siRNA
  • 小分子化療藥物

第10章 依應用領域分類的癌症治療NDDS市場

  • 化療
  • 免疫療法
  • 動態療法
  • 放射治療
  • 標靶治療

第11章 癌症治療領域以科技平台為基礎的新型藥物傳遞系統市場

  • 嵌入式倉庫系統
  • 注射用懸浮液
  • 微針系統
  • 奈米科技
    • 主動標靶化
      • 配體標靶化
      • 受體介導
    • 被動標靶化

第12章 區域癌症治療領域新型藥物傳遞系統市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 癌症治療領域新藥物遞送系統市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國癌症治療領域新型藥物遞送系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Novartis AG
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • Amgen Inc.
    • AbbVie Inc.
Product Code: MRR-521BAA36EBB7

The NDDS in Cancer Therapy Market is projected to grow by USD 32.90 billion at a CAGR of 13.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.75 billion
Estimated Year [2025] USD 13.35 billion
Forecast Year [2032] USD 32.90 billion
CAGR (%) 13.72%

Comprehensive overview of how multidisciplinary platform innovations in nanocarriers and device-based systems are redefining therapeutic strategies and clinical translation in oncology

Next-generation drug delivery systems (NDDS) are reshaping the therapeutic playbook for oncology by enabling more precise, effective, and patient-centric interventions. Advances in carrier architectures and formulation science have unlocked the ability to control pharmacokinetics, enhance tumor accumulation, and reduce off-target toxicities, thereby broadening the therapeutic index of both established cytotoxics and novel biologics. These capabilities are realized through a spectrum of material platforms that range from dendrimer-based scaffolds and exosome-inspired biomimetics to lipid nanocarriers and conventional liposomes, as well as metallic nanoparticle constructs, micelles, nanoemulsions, and polymeric nanoparticle systems. Each platform brings distinctive physicochemical attributes that influence payload loading, stability, circulation time, and tissue penetration.

Equally important is the breadth of cargo that modern NDDS can transport. The field now routinely incorporates gene therapy agents, monoclonal antibodies, oligonucleotide drugs, siRNA constructs, and small-molecule chemotherapeutics within engineered carriers, enabling combination regimens and multi-modal modes of action. These payloads map to clinical applications that include chemotherapy, immunotherapy, photodynamic therapy, radiotherapy, and targeted therapy, and they frequently require bespoke delivery considerations to reach intracellular or tumor microenvironment targets. Complementing material and payload innovation are emergent technology platforms such as implantable depot systems, injectable suspensions, microneedle systems, and nanotechnology-based constructs. Within nanotechnology, design choices emphasize either active targeting strategies, which use ligand-directed or receptor-mediated mechanisms to engage specific cell populations, or passive targeting approaches that exploit size, surface chemistry, and the enhanced permeability and retention effect to concentrate agents in tumor tissue.

This introduction frames a landscape in which engineering, biology, regulatory science, and clinical practice converge. Translational progress depends not only on demonstrating enhanced efficacy and safety in controlled studies, but also on solving downstream challenges in scalable manufacturing, reproducible characterization, and regulatory alignment. As a result, stakeholders from discovery scientists and formulation engineers to clinical operations and commercial teams must coordinate across increasingly multidisciplinary pathways to advance NDDS from concept to clinic.

Key technological, clinical, and manufacturing inflection points that collectively reconfigure how targeted delivery and combination regimens are developed and commercialized in cancer care

The landscape for oncology drug delivery is undergoing transformative shifts driven by technological convergence, regulatory evolution, and evolving clinical paradigms. A critical shift is the maturation of active targeting approaches; ligand-mediated and receptor-directed strategies are moving beyond proof-of-concept to demonstrate reproducible target engagement and improved therapeutic windows in selective indications. At the same time, passive targeting strategies have evolved through refined particle engineering and surface chemistries that extend circulation half-life and modulate tumor penetration kinetics. These scientific advances are accelerated by parallel progress in payload modalities, notably the integration of nucleic acid therapeutics such as siRNA and oligonucleotide drugs with lipid and polymeric carriers, enabling intracellular gene modulation previously unattainable with traditional formulations.

Another major shift is the growing prominence of combination regimens in which NDDS enable co-delivery of immunomodulators alongside cytotoxics or targeted agents to reshape the tumor microenvironment. Here, the coupling of formulation innovation to immunotherapy mechanisms has created new trial designs and regulatory considerations. Concurrently, advances in implantable depot systems and microneedle platforms are expanding access pathways for localized delivery, which can reduce systemic exposure and improve adherence. From a manufacturing and commercialization perspective, the industry is witnessing investments in modular and continuous production technologies to improve batch-to-batch consistency and scale while maintaining stringent controls on critical quality attributes. Finally, data-driven personalization, including biomarker-driven patient selection and companion diagnostics, is becoming a cornerstone of clinical development strategies, ensuring that delivery innovations are paired with patient populations most likely to benefit. Together, these shifts reposition drug delivery as a central enabler of next-generation oncology therapeutics rather than a peripheral formulation exercise.

Analysis of how recent tariff policy shifts initiated in 2025 have reshaped supply chain resilience, sourcing strategies, and commercial considerations for advanced oncology delivery systems

The implementation of new tariff measures in the United States in 2025 has introduced a set of operational and strategic pressures on the NDDS ecosystem, influencing supply chains, sourcing strategies, and cost structures. Immediate operational impacts were felt in the procurement of specialized raw materials and advanced excipients frequently sourced through global suppliers, including certain lipids, specialty polymers, and reagent-grade metals used in metallic nanoparticles. As companies adjusted to altered input costs and lead times, procurement teams prioritized supplier diversification, qualification of alternative suppliers, and bilateral agreements that include co-investment in local manufacturing capabilities. These adjustments have hastened conversations around regionalization of supply, with an intensified focus on building resilient domestic or nearshore capacity for critical components and contract manufacturing activities.

For R&D and clinical programs, the tariff-driven environment emphasized the value of flexible formulation approaches that reduce reliance on single-source inputs. Development teams accelerated the assessment of alternative chemistries and process routes to mitigate exposure to tariff volatility. In parallel, strategic alliances and licensing deals became more prevalent as firms sought to secure access to essential technologies and to share the financial burden of localized manufacturing investments. From a commercial standpoint, pricing strategies and contracting negotiations have had to account for potential margin compression while maintaining competitiveness in global markets. These dynamics also influenced regional deployment decisions; emerging plans to expand capacity in jurisdictions with preferential trade arrangements or established manufacturing ecosystems have gained traction. Ultimately, the tariff environment compelled organizations to balance near-term cost management with longer-term investments in supply chain robustness, regulatory alignment for new manufacturing sites, and targeted vertical integration to safeguard critical capabilities.

Insightful segmentation-driven perspective revealing how product classes, payload categories, clinical applications, and platform technologies align to inform strategic development priorities

Segmentation clarity is essential to understand where technological value and clinical opportunity intersect across the NDDS landscape. When dissected by product type, distinct value propositions emerge: dendrimers and polymeric nanoparticles offer tunable architectures for precise drug loading and controlled release; exosome-inspired platforms provide biomimetic interfaces for immune modulation and intracellular trafficking; lipid nanocarriers and liposomes remain central for nucleic acid and small-molecule payloads because of their biocompatibility and regulatory precedent; metallic nanoparticles enable diagnostic and theranostic roles through imaging contrast and photothermal modalities; micelles and nanoemulsions present low-cost, scalable options for solubilizing hydrophobic chemotherapeutics. Each class carries unique development pathways and translational bottlenecks, and development prioritization should align platform attributes with clinical unmet needs.

In terms of drug type, the integration of gene therapy agents and siRNA into delivery constructs necessitates high-performance encapsulation and endosomal escape solutions, while monoclonal antibodies and oligonucleotide drugs impose distinct stability and conjugation requirements. Small-molecule chemotherapeutics, conversely, often benefit from carriers that modulate pharmacokinetics to reduce systemic toxicity and enhance tumor exposure. Application-focused segmentation elucidates opportunity clusters: chemotherapy remains a dominant use case for improved safety and targeted exposure; immunotherapy benefits from delivery systems that modulate antigen presentation and immune cell trafficking; photodynamic and radiotherapy adjuncts gain from carriers that localize photosensitizers or radiosensitizers within tumor microenvironments; targeted therapy is increasingly paired with nanocarriers that enable intracellular delivery to otherwise inaccessible targets.

Evaluating technology platforms reveals implementation pathways and clinical adoption drivers. Implantable depot systems provide sustained local concentrations and are attractive for site-specific control in solid tumors. Injectable suspensions and microneedle systems support ambulatory care and enhanced patient adherence, reducing reliance on infusion centers. Within the broader nanotechnology domain, design trade-offs between passive and active targeting shape efficacy outcomes: passive targeting leverages colloidal stability and size to exploit tumor physiology, whereas active targeting uses ligand-directed or receptor-mediated mechanisms to enhance cell specificity. The hierarchical segmentation across product types, drug classes, applications, and platform technologies therefore guides investment prioritization and clinical translation strategies based on technical feasibility, regulatory precedent, and patient care models.

Regional dynamics and strategic imperatives that determine how clinical development, manufacturing scale-up, and commercial deployment should be tailored across three major global market spheres

Regional dynamics significantly influence development pathways, partner selection, and commercialization strategies for NDDS. In the Americas, strong venture capital ecosystems, dense biotech clusters, and an active clinical trial environment underpin rapid translational activity. The regulatory framework emphasizes early engagement and guidance for novel modalities, and there is substantial capacity in both specialized contract development and manufacturing organizations to support scale-up efforts. These factors create an environment where first-in-class technologies frequently reach clinical milestones and attract strategic partnerships.

Europe, the Middle East and Africa present a heterogeneous landscape in which advanced regulatory expertise and academic research centers drive scientific innovation, while market access and reimbursement frameworks can vary widely across jurisdictions. European innovators often benefit from collaborative networks and public-private partnerships that advance translational science, whereas emerging markets within the broader region may prioritize cost-effective and scalable delivery approaches that address access and infrastructure constraints.

Asia-Pacific is characterized by rapidly expanding manufacturing capacity, significant government-led investments in biotech infrastructure, and large patient populations that are attractive for clinical development and real-world evidence generation. Local champions in several markets have demonstrated strength in formulation development and high-throughput manufacturing, which supports global supply diversification strategies. Across these regions, differentiated commercialization pathways-ranging from premium, high-touch launch models in developed markets to pragmatic, cost-sensitive approaches in certain emerging markets-require adaptive strategies that align regulatory tactics, partnership models, and production footprints with regional access and reimbursement landscapes.

Strategic behaviors, partnership archetypes, and operational priorities that define how leading organizations convert delivery platform strengths into clinical and commercial advantage

Competitive behavior across the NDDS ecosystem reflects a mix of vertical integration, focused specialization, and strategic partnering. Established pharmaceutical companies increasingly pursue in-licensing and selective acquisitions to incorporate delivery expertise that complements therapeutic pipelines, while specialized contract developers and technology-focused start-ups concentrate on platform maturation and regulatory proof points. There is a clear trend toward alliances that combine formulation know-how with clinical development capabilities, enabling faster proof-of-concept and de-risking of first-in-human studies.

Key operational imperatives observed among leading organizations include investment in robust CMC development, rigorous characterization of critical quality attributes, and early alignment with regulators on comparability strategies for complex formulations. Companies that have advanced clinical-stage NDDS programs often invest in orthogonal analytical methods and process controls that reduce variability and facilitate scale-up. Intellectual property strategies commonly balance core composition-of-matter protections with targeted method and use patents, while freedom-to-operate assessments guide partnership and licensing negotiations. In addition, cross-sector collaborations with diagnostics and biomarker providers are shaping companion diagnostic strategies that link delivery innovations to patient selection criteria. Collectively, these behaviors underscore the importance of integrated technical, regulatory, and commercial planning to translate platform advantage into sustainable market adoption.

Practical and high-impact strategic recommendations for executive teams to accelerate development, mitigate operational risks, and secure regulatory and commercial advantage in advanced oncology delivery

Leaders in the NDDS space must adopt actionable strategies that align technical innovation with commercial viability and regulatory pragmatism. First, prioritize early and continuous regulatory engagement to define acceptable endpoints, comparator strategies, and analytical expectations; this reduces late-stage surprises and accelerates development timelines. Second, invest in modular, scalable manufacturing solutions and multi-sourcing strategies that reduce exposure to supply disruptions and tariff-related volatility. Third, design clinical development programs that integrate biomarker-driven patient selection and adaptive trial designs to enhance signal detection and optimize resource allocation. Fourth, pursue partnerships that pair formulation expertise with clinical development capabilities, including alliances with groups experienced in device integration for implantable and microneedle-based platforms.

Fifth, align portfolio decisions with differentiated value propositions, focusing resources on platform-payload combinations likely to demonstrate clinically meaningful improvements in therapeutic index or patient experience. Sixth, strengthen intellectual property and data exclusivity strategies that cover both composition and manufacturing innovations, and consider defensive filings where platform modularity might invite competition. Seventh, embed real-world evidence and health economics planning into development to support payer discussions and reimbursement models. Finally, cultivate multidisciplinary teams that bridge materials science, translational biology, regulatory affairs, and commercial strategy to ensure that technical advances are translated into viable therapeutic solutions and sustainable business models.

Robust and multidisciplinary research approach combining expert interviews, technology readiness assessments, and evidence synthesis to validate translational and commercial conclusions

The research underpinning this executive summary integrates multiple evidence streams to generate nuanced, action-oriented insights. Primary inputs included structured interviews with formulation scientists, clinical development leads, manufacturing executives, and regulatory specialists across biotech, pharmaceutical, and contract service organizations. These conversations explored technical challenges, commercialization priorities, and anticipated shifts in development strategies. Secondary research drew on peer-reviewed literature, clinical trial registries, patent filings, and public regulatory guidance documents to triangulate trends in platform performance, clinical endpoints, and approval pathways.

Analytical methods combined qualitative synthesis with technology readiness assessments that evaluated translational hurdles such as encapsulation efficiency, stability, and manufacturability. Supply chain and policy impacts were examined through scenario analysis that considered raw material sourcing, regional manufacturing capacity, and trade policy shifts. Validation of key findings was achieved through workshops with subject-matter experts and review of recent case studies that illustrate successful translation of NDDS into clinical and commercial products. This multi-method approach ensures that conclusions are grounded in technical reality, informed by stakeholder perspectives, and applicable to strategic decision-making in both development and commercialization contexts.

Synthesis of how technological progress, clinical strategy, and operational readiness jointly determine which delivery innovations will meaningfully transform oncology care moving forward

The current trajectory of next-generation drug delivery systems in oncology points toward an era in which delivery innovation is integral to therapeutic efficacy, patient experience, and commercial differentiation. Engineering advances across dendrimers, lipid-based carriers, exosome-inspired constructs, and implantable devices enable precise spatial and temporal control of drug exposure, while the incorporation of nucleic acid therapeutics and targeted biologics broadens the range of addressable molecular pathways. These technical advances are matched by shifts in clinical development paradigms that emphasize biomarker-driven patient selection and combination strategies integrating immunomodulation and localized delivery.

However, realizing the full potential of NDDS requires deliberate attention to manufacturing scale-up, robust characterization methods, and regulatory engagement early in development. Policy shifts and trade dynamics have underscored the need for resilient supply chains and flexible sourcing strategies. Organizations that combine disciplined CMC practices with strategic partnerships, adaptive clinical designs, and patient-centered delivery models will be best positioned to translate platform strengths into tangible clinical and commercial outcomes. The field is poised for continued innovation, but success will hinge on integrating technical excellence with pragmatic execution across regulatory, manufacturing, and market access domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical translation of tumor microenvironment responsive nanoparticle platforms enhancing selective drug release
  • 5.2. Development of multifunctional lipid nanoparticle systems co-delivering siRNA and chemotherapeutics for resistant tumors
  • 5.3. Engineering of biomimetic exosome-inspired nanocarriers for targeted immunomodulatory cargo delivery
  • 5.4. Integration of real-time imaging modalities within theranostic nanoparticle drug delivery systems for monitoring treatment
  • 5.5. Advancement in stimuli responsive polymeric micelles exploiting tumor pH and enzyme triggers for on-demand drug release
  • 5.6. Adoption of personalized nanoparticle vaccines combining neoantigen peptides and adjuvants for cancer immunotherapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. NDDS in Cancer Therapy Market, by Product Type

  • 8.1. Dendrimers
  • 8.2. Exosomes
  • 8.3. Lipid Nanocarriers
  • 8.4. Liposomes
  • 8.5. Metallic Nanoparticles
  • 8.6. Micelles
  • 8.7. Nanoemulsions
  • 8.8. Polymeric Nanoparticles

9. NDDS in Cancer Therapy Market, by Drug Type

  • 9.1. Gene Therapy Agents
  • 9.2. Monoclonal Antibodies
  • 9.3. Oligonucleotide Drugs
  • 9.4. SiRNA
  • 9.5. Small-Molecule Chemotherapeutics

10. NDDS in Cancer Therapy Market, by Application

  • 10.1. Chemotherapy
  • 10.2. Immunotherapy
  • 10.3. Photodynamic Therapy
  • 10.4. Radiotherapy
  • 10.5. Targeted Therapy

11. NDDS in Cancer Therapy Market, by Technology Platform

  • 11.1. Implantable Depot Systems
  • 11.2. Injectable Suspensions
  • 11.3. Microneedle Systems
  • 11.4. Nanotechnology
    • 11.4.1. Active Targeting
      • 11.4.1.1. Ligand Targeted
      • 11.4.1.2. Receptor Mediated
    • 11.4.2. Passive Targeting

12. NDDS in Cancer Therapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. NDDS in Cancer Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. NDDS in Cancer Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Johnson & Johnson
    • 15.3.2. F. Hoffmann-La Roche Ltd
    • 15.3.3. Pfizer Inc.
    • 15.3.4. Novartis AG
    • 15.3.5. AstraZeneca PLC
    • 15.3.6. Merck & Co., Inc.
    • 15.3.7. Bristol-Myers Squibb Company
    • 15.3.8. Sanofi S.A.
    • 15.3.9. Amgen Inc.
    • 15.3.10. AbbVie Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NDDS IN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIGAND TARGETED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIGAND TARGETED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIGAND TARGETED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIGAND TARGETED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIGAND TARGETED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIGAND TARGETED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RECEPTOR MEDIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RECEPTOR MEDIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RECEPTOR MEDIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RECEPTOR MEDIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RECEPTOR MEDIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RECEPTOR MEDIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PASSIVE TARGETING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PASSIVE TARGETING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PASSIVE TARGETING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PASSIVE TARGETING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PASSIVE TARGETING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PASSIVE TARGETING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY ACTIVE TARGETING, 2025-2032 (USD MILLION)
  • TABLE 303. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 312. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 313. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC NDDS IN CANCER T